0.3548
前日終値:
$0.377
開ける:
$0.377
24時間の取引高:
1.59M
Relative Volume:
2.53
時価総額:
$20.73M
収益:
-
当期純損益:
$-123.46M
株価収益率:
-0.137
EPS:
-2.59
ネットキャッシュフロー:
$-104.11M
1週間 パフォーマンス:
+0.80%
1か月 パフォーマンス:
-12.63%
6か月 パフォーマンス:
-28.98%
1年 パフォーマンス:
-79.13%
Bioatla Inc Stock (BCAB) Company Profile
BCAB を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
BCAB
Bioatla Inc
|
0.3548 | 22.02M | 0 | -123.46M | -104.11M | -2.59 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-11-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2022-09-15 | 開始されました | JMP Securities | Mkt Outperform |
2022-05-05 | ダウングレード | Credit Suisse | Outperform → Neutral |
2022-03-21 | 開始されました | H.C. Wainwright | Buy |
2021-10-15 | 再開されました | BTIG Research | Buy |
2021-06-28 | 開始されました | ROTH Capital | Buy |
2021-05-05 | 再開されました | Credit Suisse | Outperform |
2021-04-26 | 再開されました | Credit Suisse | Outperform |
2021-01-11 | 開始されました | BTIG Research | Buy |
2021-01-11 | 開始されました | Credit Suisse | Outperform |
2021-01-11 | 開始されました | JP Morgan | Overweight |
2021-01-11 | 開始されました | Jefferies | Buy |
すべてを表示
Bioatla Inc (BCAB) 最新ニュース
BioAtla Inc. Stock Analysis and ForecastOutstanding risk-reward balance - PrintWeekIndia
What drives BioAtla Inc. stock priceTriple-digit return opportunities - Autocar Professional
What analysts say about BioAtla Inc. stockConsistently high returns - Autocar Professional
Is Now The Time To Buy BioAtla Inc (NASDAQ: BCAB) Stock? - Stocksregister
Is BioAtla Inc. a good long term investmentHigh-yield market plays - jammulinksnews.com
Is BioAtla Inc. stock a good hedge against inflationFree Consultation - Newser
What analysts say about BioAtla Inc. stock outlookFast Gains With Reduced Risk - beatles.ru
BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting - The Manila Times
What makes BioAtla Inc. stock price move sharplyTrending Stock Alert - Newser
Why BioAtla Inc. stock attracts strong analyst attentionStable Stocks With High Yield - Newser
How BioAtla Inc. stock performs during market volatilityPortfolio Boosting Stock Alerts - Newser
BioAtla (NASDAQ:BCAB) Stock Price Up 2.6% – Here’s Why - Defense World
BioAtla presents Phase I data of BA3182 for metastatic adenocarcinoma - Yahoo Finance
BioAtla Approves 2025 Corporate Bonus Plan - TipRanks
BioAtla, Inc. (NASDAQ:BCAB) Shares Purchased by Two Sigma Investments LP - Defense World
Jane Street Group LLC Purchases 100,204 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla, Inc. (NASDAQ:BCAB) Stock Position Lowered by Two Sigma Advisers LP - Defense World
Millennium Management LLC Cuts Stock Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla (NASDAQ:BCAB) Upgraded by Wall Street Zen to Hold Rating - Defense World
BioAtla presents Phase 2 Oz-V clinical trial data at ASCO 2025 - MSN
Why Did BioAtla Inc (NASDAQ: BCAB) Drop So Much? - Stocksregister
BioAtla reports promising trial results for cancer drug By Investing.com - Investing.com South Africa
BioAtla reports promising trial results for cancer drug - Investing.com
BioAtla (BCAB) Showcases Promising Data for Ozuriftamab Vedotin in Key Cancer Trial | BCAB Stock News - GuruFocus
Bioatla Inc (BCAB) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):